2 results
Approved WMOCompleted
The primary efficacy endpoint is treatment success in the therapy for mild to moderate Crohn*s disease with fisultas defined by: - A reduction of at least 50% in the number of draining fistulas at both week 4 and week 8
Approved WMORecruiting
OBJECTIVES - Phase 2 (not to be conducted in NL):Phase 2 Primary Objective:- Identify a setrusumab dosing strategy in subjects with OI Phase 2 Secondary Objectives:- Evaluate the PK of setrusumab doses in subjects with OI- Determine the PD effects…